| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
HCV
NM-107 targets the HCV NS5B RNA-dependent RNA polymerase, acting as a nucleoside inhibitor that terminates viral RNA chain elongation. |
|---|---|
| ln Vitro |
In Huh7-1 cells and cell culture-propagated HCV, NM107 (25 μM; 24 hours) treatment reduces intracellular RNA levels and extracellular viral titers.
In vitro, NM-107 inhibits HCV replication with an EC50 of 1.85 μM in wild-type replicon cells. It also inhibits bovine viral diarrhea virus (BVDV) replication with an EC50 of 2.2 μM and human coronavirus (HCoV) with an EC50 of 90 μM. It demonstrates an IC50 of 7.0 μM against HCV RNA replication in vitro. |
| ln Vivo |
In vivo, NM-107 has shown antiviral activity in animal models as a nucleoside inhibitor. Its active triphosphate form is the primary inhibitor of viral polymerase, leading to a reduction in viral load. It has been investigated as a potential therapeutic agent for HCV infection.
|
| Enzyme Assay |
In vitro enzyme assays for NM-107 involve measuring the inhibition of the HCV NS5B polymerase. The enzyme is incubated with a RNA template, primer, and nucleotide substrates, including the compound's triphosphate form (NM-107-TP), which is the active species. The incorporation of the nucleotide analog into the growing RNA chain leads to chain termination, which is measured to determine the inhibitory potency.
|
| Cell Assay |
Cell Line: Huh7-1 cells and HCV (HCVcc) propagated in cell culture
Concentration: 25 μM
Incubation Time: 24 hours
Result: The reduction of intracellular RNA levels coincided with the titers of extracellular viruses.
In vitro cellular assays for NM-107 use HCV subgenomic replicon cell lines. Cells are treated with the compound, and viral RNA replication is quantified by real-time RT-PCR. The compound is typically tested in a panel of cell lines, including those harboring wild-type and drug-resistant replicons, to determine its EC50 and selectivity index. Cytotoxicity is assessed in parallel to ensure the antiviral effect is not due to general cell death. |
| Animal Protocol |
In vivo animal studies for NM-107 are conducted using mouse models of HCV infection, such as transgenic mice expressing the HCV replicon or chimeric mice with humanized livers. The compound is administered orally or intraperitoneally, and viral load in the serum or liver is measured to assess efficacy. Other models using bovine viral diarrhea virus (BVDV) in calves have also been used.
|
| ADME/Pharmacokinetics |
As a nucleoside analog, NM-107 is a prodrug that requires intracellular phosphorylation to its active triphosphate form. PK studies focus on the formation and persistence of the active triphosphate in target cells (hepatocytes). The compound has been evaluated in preclinical models for its oral bioavailability and liver distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for NM-107 are not detailed in publicly available sources. As a nucleoside analog, potential toxicity concerns include mitochondrial toxicity and effects on host DNA polymerases. Standard preclinical safety assessments would be required for its development as an antiviral agent.
|
| References |
|
| Additional Infomation |
A nucleoside analogue with anti-hepatitis C virus (HCV) activity. Phosphorylation of this metabolite to its 5-triphosphate form inhibits viral RNA chain elongation and the activity of viral RNA-dependent RNA polymerase. This blocks the production of HCV RNA, thereby inhibiting viral replication.
NM-107 is the parent nucleoside of the clinically approved prodrug NM-283 (Valopicitabine). It is a 2'-C-methylcytidine. It has broad-spectrum antiviral activity against flavi- and pestiviruses. Its development as a direct antiviral for HCV was largely superseded by more effective direct-acting antivirals. |
| Molecular Formula |
C10H15N3O5
|
|---|---|
| Molecular Weight |
257.2432
|
| Exact Mass |
257.101
|
| Elemental Analysis |
C, 46.69; H, 5.88; N, 16.33; O, 31.10
|
| CAS # |
20724-73-6
|
| PubChem CID |
500902
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
523.9±60.0 °C at 760 mmHg
|
| Melting Point |
243-245ºC
|
| Flash Point |
270.7±32.9 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.700
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
424
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@](C([H])([H])[H])([C@]1([H])N1C(N=C(C([H])=C1[H])N([H])[H])=O)O[H])O[H]
|
| InChi Key |
PPUDLEUZKVJXSZ-VPCXQMTMSA-N
|
| InChi Code |
InChI=1S/C10H15N3O5/c1-10(17)7(15)5(4-14)18-8(10)13-3-2-6(11)12-9(13)16/h2-3,5,7-8,14-15,17H,4H2,1H3,(H2,11,12,16)/t5-,7-,8-,10-/m1/s1
|
| Chemical Name |
4-amino-1-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
|
| Synonyms |
NM-107; NM 107; NM107; 2'-C-Methylcytidine; 2'-C-MeC; 2-CMC; mCyd ; 2'CMeC; 2CMC.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (388.74 mM)
H2O : ≥ 50 mg/mL (194.37 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (9.72 mM) Solubility in Formulation 5: 50 mg/mL (194.37 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8874 mL | 19.4371 mL | 38.8742 mL | |
| 5 mM | 0.7775 mL | 3.8874 mL | 7.7748 mL | |
| 10 mM | 0.3887 mL | 1.9437 mL | 3.8874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
